BACKGROUND: The present study examined if increases in creatine kinase (CK) levels during high-dose atorvastatin treatment are associated with changes in skeletal muscle function and symptoms. METHODS: The Effect of Statins on Muscle Performance study (STOMP) investigated the effects of atorvastatin 80 mg daily for 6 months on muscle performance, exercise capacity, and the incidence of statin-associated muscle complaints in healthy adults. RESULTS:CK levels increased with atorvastatin (n = 202) from 132.3 ± 120.9 U/L (mean ± SD) at baseline to 159.7 ± 170.4 and 153.1 ± 139.4 U/L at 3 and 6 months, respectively (P ≤ 0.002 for both). Changes in CK with atorvastatin treatment were not associated with changes in muscle function or the incidence of myalgia. More subjects on atorvastatin (n = 24) compared to placebo (n = 12 of 217) doubled their CK level at 6 months (P = 0.02). No differences in muscle function or physical activity were observed between atorvastatin-treated subjects who did or did not double their CK. CONCLUSIONS: Results of the present investigation extend the findings of STOMP by demonstrating that greater increases in CK levels with high-dose atorvastatin treatment did not deleteriously impact skeletal muscle function or predict skeletal muscle complaints. This study was registered at ClinicalTrials.gov (NCT00609063).
RCT Entities:
BACKGROUND: The present study examined if increases in creatine kinase (CK) levels during high-dose atorvastatin treatment are associated with changes in skeletal muscle function and symptoms. METHODS: The Effect of Statins on Muscle Performance study (STOMP) investigated the effects of atorvastatin 80 mg daily for 6 months on muscle performance, exercise capacity, and the incidence of statin-associated muscle complaints in healthy adults. RESULTS: CK levels increased with atorvastatin (n = 202) from 132.3 ± 120.9 U/L (mean ± SD) at baseline to 159.7 ± 170.4 and 153.1 ± 139.4 U/L at 3 and 6 months, respectively (P ≤ 0.002 for both). Changes in CK with atorvastatin treatment were not associated with changes in muscle function or the incidence of myalgia. More subjects on atorvastatin (n = 24) compared to placebo (n = 12 of 217) doubled their CK level at 6 months (P = 0.02). No differences in muscle function or physical activity were observed between atorvastatin-treated subjects who did or did not double their CK. CONCLUSIONS: Results of the present investigation extend the findings of STOMP by demonstrating that greater increases in CK levels with high-dose atorvastatin treatment did not deleteriously impact skeletal muscle function or predict skeletal muscle complaints. This study was registered at ClinicalTrials.gov (NCT00609063).
Authors: Beth A Parker; Amanda L Augeri; Jeffrey A Capizzi; Kevin D Ballard; Christopher Troyanos; Aaron L Baggish; Pierre A D'Hemecourt; Paul D Thompson Journal: Am J Cardiol Date: 2011-10-28 Impact factor: 2.778
Authors: Monica J Hubal; Joseph M Devaney; Eric P Hoffman; Edward J Zambraski; Heather Gordish-Dressman; Amy K Kearns; Justin S Larkin; Kasra Adham; Ronak R Patel; Priscilla M Clarkson Journal: J Appl Physiol (1985) Date: 2010-03-25
Authors: Kari Soininen; Mikko Niemi; Esa Kilkki; Timo Strandberg; Kari T Kivistö Journal: Basic Clin Pharmacol Toxicol Date: 2006-01 Impact factor: 4.080
Authors: Patrick W J C Serruys; Pim de Feyter; Carlos Macaya; Norbert Kokott; Jacques Puel; Matthias Vrolix; Angelo Branzi; Marcelo C Bertolami; Graham Jackson; Bradley Strauss; Bernhard Meier Journal: JAMA Date: 2002-06-26 Impact factor: 56.272
Authors: J R Downs; M Clearfield; S Weis; E Whitney; D R Shapiro; P A Beere; A Langendorfer; E A Stein; W Kruyer; A M Gotto Journal: JAMA Date: 1998-05-27 Impact factor: 56.272
Authors: R H Bradford; C L Shear; A N Chremos; C A Dujovne; F A Franklin; R B Grillo; J Higgins; A Langendorfer; D T Nash; J L Pool Journal: Am J Cardiol Date: 1994-10-01 Impact factor: 2.778
Authors: Wolfgang Dichtl; Jozef Dulak; Matthias Frick; Hannes F Alber; Severin P Schwarzacher; Mikko P S Ares; Jan Nilsson; Otmar Pachinger; Franz Weidinger Journal: Arterioscler Thromb Vasc Biol Date: 2003-01-01 Impact factor: 8.311
Authors: Allie Leblanc; Linda S Pescatello; Beth A Taylor; Jeffrey A Capizzi; Priscilla M Clarkson; C Michael White; Paul D Thompson Journal: Springerplus Date: 2015-09-28
Authors: William M Southern; Anna S Nichenko; Daniel D Shill; Corey C Spencer; Nathan T Jenkins; Kevin K McCully; Jarrod A Call Journal: PLoS One Date: 2017-02-16 Impact factor: 3.240
Authors: Hae R Chung; Mayand Vakil; Michael Munroe; Alay Parikh; Benjamin M Meador; Pei T Wu; Jin H Jeong; Jeffrey A Woods; Kenneth R Wilund; Marni D Boppart Journal: PLoS One Date: 2016-12-09 Impact factor: 3.240
Authors: Alessandro Trentini; Savino Spadaro; Valentina Rosta; Maria C Manfrinato; Carlo Cervellati; Francesca Dalla Corte; Stefania Hanau; Carlo A Volta; Tiziana Bellini Journal: Biochem Med (Zagreb) Date: 2018-12-15 Impact factor: 2.313